Minister for Jobs, Enterprise and Innovation, Richard Bruton TD, announced on the 27th July 2015, that PAREXEL International Corporation (NASDAQ: PRXL) is opening a new global decision-making hub for the Company in Kilmainham, Dublin 8. PAREXEL has plans to hire an additional 130 people over the next 12 to 18 months across all areas of their business. These areas include clinical, technology, legal, consulting, and logistics. Senior decision-making roles in the Kilmainham location are also up for grabs and recruitment for these positions is now underway. Presently seventy employees are employed with their leading global biopharmaceutical services provider and company.
“Life sciences are a key sector which we have targeted as part of our Action Plan for Jobs, and in recent years we have seen an impressive jobs performance in this area, both in Dublin and across the country. Today’s announcement that PAREXEL is adding 130 jobs in Kilmainham is a great boost and an example of the wide range of different types of jobs that Ireland can attract in this sector. I look forward to working closely with Douglas and the team at PAREXEL as they roll out this project,” the Minister said.
Investment supported by the Department of Jobs, Enterprise and Innovation, is being provided through IDA Ireland. PAREXEL operates in 80 locations in 51 countries around the world, with 17,440 employees worldwide in the third quarter, with their headquarters located near Boston, Massachusetts.
“Europe is important to our growth and business strategy and Ireland specifically is a key country from which we can better serve our customers and continue our growth. This office will be a global decision-making hub for our Company. Senior leaders based here will be making strategic decisions for the Company worldwide, and this office will play a critical role in continuing to bring PAREXEL’s global brand to the world,” said Douglas A. Batt, Senior Vice President and General Counsel for PAREXEL.
IDA’s CEO Martin Shanahan said: “This is an endorsement of the skills available to biopharmaceutical companies here. PAREXEL will be joining a very large cluster of biopharma companies that have already chosen Ireland as a place to locate business.”
He also said: “PAREXEL’s decision to locate in Ireland is an endorsement of the skills available to biopharmaceutical companies here. Ireland is the perfect place in which to locate a Global Hub – our location facilities access into Europe, the Middle East and further afield. IDA Ireland has targeted the Life Sciences, and in particular, the Biopharmaceuticals sector for several years now.”
The IDA (Inward Investment Promotion Agency) partners with potential and existing investors to help them establish or expand their operations in Ireland and is a non-commercial, semi-state body promoting foreign direct investment in Ireland through a wide range of services.
PAREXEL International Corporation is an organization that provides contract research, consulting, medical communications, and technology solutions and services to industries in the pharmaceutical, biotechnology and medicals device sectors. Developing and commercialising drugs, clinical pharmacology, clinical trials management and medical education has made PAREXEL experts in the market place.